Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xalatan delivery device study in glaucoma
NCT00143429Phase 2Withdrawn
- Sponsor
- Viatris
- Modality
- Orthosteric Ligands
01
Overview
Phase 2 trial of latanoprost in Open-angle glaucoma (OAG) and ocular hypertension (3 arms), sponsored by Viatris. Primary endpoint: Intraocular Pressure. Status: withdrawn.
02
Drugs
latanoprost
03
Conditions
Open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT00143429.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00143429.